Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301-Reference-Cited by-同舟云学术

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301

Published:2011-09 Issue:13 Volume:47 Page:2052-2059
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Thomas Huw D.,Wang Lan-Zhen,Roche Celine,Bentley Johanne,Cheng Yuzhu,Hardcastle Ian R.,Golding Bernard T.,Griffin Roger J.,Curtin Nicola J.,Newell David R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Cell cycle kinases as therapeutics for cancer;Lapenna;Nat Rev Drug Discov,2009

2. Cyclin-dependent kinase pathways as targets for cancer treatment;Shapiro;J Clin Oncol,2006

3. CDK inhibitors in cancer therapy: what is next?;Malumbres;Trends in Pharm Sci,2007

4. Distinct roles for cyclin-dependent kinases in cell cycle control;Van der Heuvel;Science,1993

5. S and G2 phase roles for CDK2 revealed by inducible expression of a dominant-negative mutant in human cells;Hu;Mol Cell Biol,2001

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

2. An overview of CDK3 in cancer: clinical significance and pharmacological implications;Pharmacological Research;2022-06

3. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity;Chemical and Pharmaceutical Bulletin;2021-01-01

4. Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures;European Journal of Medicinal Chemistry;2019-02

5. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?;Journal of Medicinal Chemistry;2018-09-20